Cargando…
Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer
SIMPLE SUMMARY: Colorectal cancer is the third most common disease and the second most common cause of death around the world. The drug for second-line treatment is determined by the type of drug used for first-line treatment and the biomarker status. As biomarkers, the RAS gene, BRAF gene, and dMMR...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526327/ https://www.ncbi.nlm.nih.gov/pubmed/37760533 http://dx.doi.org/10.3390/cancers15184564 |